o_19nh7smpi1u37npm1scb1pfbjrda.pdf
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
3 Marketed Products<br />
3.1 Key Marketed Products<br />
3.1.1 Immunotherapies<br />
3.1.2 Targeted Therapies<br />
3.1.3 Hyperthermic Intraperitoneal Chemotherapy<br />
3.2 Heat Map for Marketed Products<br />
4 Pipeline Analysis<br />
4.1 Overall Pipeline<br />
4.2 Pipeline Analysis by Molecule Type<br />
4.3 Pipeline Analysis by Mechanism of Action<br />
4.4 Clinical Trials<br />
4.5 Failure Rate<br />
4.6 Clinical Trial Size<br />
4.7 Duration<br />
4.8 Promising Drug Candidates in Pipeline<br />
4.8.1 Lonsurf (TAS-102 (tipiracil + trifluridine)) – Taiho Pharmaceutical<br />
4.8.2 Cyramza – ramucirumab – Eli Lilly and Company<br />
4.8.3 TS-1/Teysuno (tegafur + gimeracil + oteracil) – Taiho Pharmaceutical<br />
4.8.4 CPP-1X (eflornithine hydrochloride) + sulindac – Cancer Prevention Pharmaceuticals<br />
4.8.5 MelCancerVac – DanDrit Biotech<br />
4.8.6 Xilonix – XBiotech
Change language